Clinical and Biologic Significance of <i>MYC</i> Genetic Mutations in <i>De Novo</i> Diffuse Large B-cell LymphomaZijun Y. Xu‐Monette, Ken H. Young, Qipan Deng et al.|Clinical Cancer Research|2016Cited by 66
Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium ProgramYong Li, Ken H. Young, Michael W. Gordon et al.|Blood|2013Cited by 48
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell LymphomaYi Xia, L. Jeffrey Medeiros, J. Han van Krieken et al.|UNC Libraries|2020Cited by 9
Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of ActionYuqin Song, Jun Zhu, Lei Wang et al.|Blood|2020Cited by 4
Supplementary Figures 1-8 from Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15aTengteng Yu, Mu Hao, Chenxing Du et al.|Unknown|2023Cited by 0